 Bradley Haverkos
Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, T-Cell | 7 | 2024 | 21 | 3.200 |
Why?
| | Lymphoma, T-Cell, Peripheral | 6 | 2024 | 15 | 2.950 |
Why?
| | Lymphoma | 5 | 2023 | 178 | 2.100 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 3 | 2020 | 8 | 1.820 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 6 | 2023 | 40 | 1.810 |
Why?
| | Herpesvirus 4, Human | 6 | 2023 | 125 | 1.680 |
Why?
| | Epstein-Barr Virus Infections | 5 | 2023 | 72 | 1.650 |
Why?
| | Hematopoietic Stem Cell Transplantation | 9 | 2020 | 520 | 1.480 |
Why?
| | Skin Neoplasms | 6 | 2024 | 758 | 1.270 |
Why?
| | Transplantation Conditioning | 9 | 2020 | 150 | 1.190 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2018 | 193 | 1.170 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2023 | 71 | 1.170 |
Why?
| | Hodgkin Disease | 2 | 2018 | 120 | 1.050 |
Why?
| | Hematopoietic Stem Cell Mobilization | 2 | 2017 | 20 | 1.030 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 5 | 2023 | 97 | 0.890 |
Why?
| | Lymphoma, B-Cell | 3 | 2022 | 86 | 0.830 |
Why?
| | Graft vs Host Disease | 5 | 2020 | 212 | 0.810 |
Why?
| | Smiling | 1 | 2021 | 6 | 0.790 |
Why?
| | Thrombocytopenia | 1 | 2023 | 178 | 0.780 |
Why?
| | DNA, Viral | 3 | 2017 | 349 | 0.730 |
Why?
| | Face | 1 | 2021 | 168 | 0.700 |
Why?
| | Natural Killer T-Cells | 1 | 2020 | 63 | 0.660 |
Why?
| | Hematology | 1 | 2019 | 13 | 0.650 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 139 | 0.650 |
Why?
| | Neoplasm Recurrence, Local | 8 | 2024 | 856 | 0.640 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2017 | 665 | 0.620 |
Why?
| | Heterocyclic Compounds | 2 | 2017 | 18 | 0.610 |
Why?
| | Burkitt Lymphoma | 3 | 2021 | 52 | 0.550 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 152 | 0.530 |
Why?
| | Antineoplastic Agents | 7 | 2023 | 1879 | 0.520 |
Why?
| | Prognosis | 6 | 2021 | 3334 | 0.510 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 385 | 0.490 |
Why?
| | Antibodies, Monoclonal | 3 | 2023 | 1268 | 0.490 |
Why?
| | Viral Load | 1 | 2016 | 405 | 0.480 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2014 | 19 | 0.470 |
Why?
| | Cord Blood Stem Cell Transplantation | 3 | 2020 | 91 | 0.460 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 1353 | 0.450 |
Why?
| | Humans | 44 | 2024 | 115044 | 0.420 |
Why?
| | Rituximab | 6 | 2023 | 150 | 0.390 |
Why?
| | Mycosis Fungoides | 2 | 2023 | 61 | 0.390 |
Why?
| | Adult | 18 | 2024 | 30656 | 0.380 |
Why?
| | Treatment Outcome | 12 | 2024 | 9122 | 0.360 |
Why?
| | Survival Analysis | 6 | 2020 | 1211 | 0.350 |
Why?
| | Transplantation, Homologous | 4 | 2019 | 390 | 0.340 |
Why?
| | Immunoblastic Lymphadenopathy | 2 | 2022 | 2 | 0.330 |
Why?
| | Transplantation, Autologous | 3 | 2020 | 175 | 0.330 |
Why?
| | Middle Aged | 17 | 2023 | 26827 | 0.310 |
Why?
| | Anti-HIV Agents | 1 | 2014 | 668 | 0.300 |
Why?
| | Aged | 14 | 2021 | 19119 | 0.290 |
Why?
| | Salvage Therapy | 2 | 2019 | 126 | 0.290 |
Why?
| | Autografts | 2 | 2019 | 40 | 0.280 |
Why?
| | Aged, 80 and over | 7 | 2021 | 6357 | 0.260 |
Why?
| | Benzylamines | 2 | 2017 | 39 | 0.260 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 2 | 2015 | 11 | 0.260 |
Why?
| | Recurrence | 5 | 2020 | 941 | 0.250 |
Why?
| | Remission Induction | 3 | 2023 | 233 | 0.220 |
Why?
| | Sezary Syndrome | 1 | 2023 | 43 | 0.220 |
Why?
| | Myeloablative Agonists | 2 | 2020 | 21 | 0.220 |
Why?
| | Immunotoxins | 1 | 2023 | 33 | 0.220 |
Why?
| | Disease-Free Survival | 3 | 2021 | 617 | 0.210 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 198 | 0.200 |
Why?
| | T-Lymphocytes | 2 | 2020 | 1747 | 0.200 |
Why?
| | Male | 15 | 2021 | 55731 | 0.190 |
Why?
| | Cyclophosphamide | 4 | 2023 | 217 | 0.190 |
Why?
| | Retrospective Studies | 7 | 2023 | 12547 | 0.190 |
Why?
| | Allografts | 2 | 2020 | 124 | 0.190 |
Why?
| | Prospective Studies | 4 | 2022 | 6232 | 0.180 |
Why?
| | Female | 13 | 2021 | 59614 | 0.170 |
Why?
| | Central Nervous System Neoplasms | 1 | 2021 | 126 | 0.170 |
Why?
| | Combined Modality Therapy | 3 | 2016 | 1127 | 0.160 |
Why?
| | Thiotepa | 1 | 2018 | 19 | 0.150 |
Why?
| | Lymphoproliferative Disorders | 1 | 2018 | 46 | 0.150 |
Why?
| | Etoposide | 3 | 2023 | 148 | 0.150 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 431 | 0.150 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 182 | 0.150 |
Why?
| | Central Nervous System Diseases | 1 | 2018 | 61 | 0.150 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 636 | 0.140 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 32 | 0.140 |
Why?
| | HIV Infections | 2 | 2021 | 2470 | 0.140 |
Why?
| | Doxorubicin | 3 | 2023 | 285 | 0.140 |
Why?
| | Carcinogenesis | 1 | 2018 | 178 | 0.140 |
Why?
| | Killer Cells, Natural | 1 | 2020 | 383 | 0.140 |
Why?
| | Asparaginase | 1 | 2016 | 29 | 0.140 |
Why?
| | Antigens, CD34 | 1 | 2017 | 89 | 0.140 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2017 | 71 | 0.140 |
Why?
| | In Situ Hybridization | 1 | 2017 | 292 | 0.140 |
Why?
| | Immunotherapy | 1 | 2020 | 474 | 0.140 |
Why?
| | Biomarkers | 2 | 2016 | 3419 | 0.140 |
Why?
| | Biopsy | 2 | 2018 | 1046 | 0.130 |
Why?
| | Cell Count | 1 | 2017 | 304 | 0.130 |
Why?
| | Neoplasm Staging | 2 | 2016 | 1169 | 0.130 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 651 | 0.130 |
Why?
| | Europe | 1 | 2016 | 336 | 0.130 |
Why?
| | North America | 1 | 2016 | 259 | 0.130 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2016 | 16 | 0.130 |
Why?
| | Ohio | 1 | 2015 | 136 | 0.130 |
Why?
| | Drug Resistance | 1 | 2015 | 158 | 0.120 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1398 | 0.120 |
Why?
| | United States | 5 | 2023 | 12226 | 0.110 |
Why?
| | Hematopoietic Stem Cells | 1 | 2017 | 344 | 0.110 |
Why?
| | B-Lymphocytes | 1 | 2018 | 772 | 0.110 |
Why?
| | Young Adult | 5 | 2021 | 10498 | 0.110 |
Why?
| | Medicare | 1 | 2018 | 666 | 0.110 |
Why?
| | Vincristine | 2 | 2023 | 98 | 0.110 |
Why?
| | Academic Medical Centers | 1 | 2015 | 412 | 0.100 |
Why?
| | Adolescent | 4 | 2023 | 17864 | 0.100 |
Why?
| | Genomics | 1 | 2017 | 641 | 0.100 |
Why?
| | Prednisone | 2 | 2023 | 231 | 0.100 |
Why?
| | Gene Expression | 1 | 2017 | 1423 | 0.100 |
Why?
| | Skin | 1 | 2016 | 659 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2017 | 1144 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2023 | 115 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2019 | 4420 | 0.100 |
Why?
| | Immunotherapy, Adoptive | 2 | 2023 | 184 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1045 | 0.090 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1523 | 0.090 |
Why?
| | Melphalan | 2 | 2020 | 29 | 0.090 |
Why?
| | Vidarabine | 2 | 2020 | 26 | 0.080 |
Why?
| | Whole-Body Irradiation | 2 | 2020 | 72 | 0.080 |
Why?
| | Fetal Blood | 2 | 2020 | 270 | 0.080 |
Why?
| | Registries | 3 | 2020 | 1763 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 2 | 2021 | 814 | 0.070 |
Why?
| | Cohort Studies | 3 | 2021 | 4904 | 0.070 |
Why?
| | Lactate Dehydrogenases | 1 | 2023 | 5 | 0.060 |
Why?
| | Disease Management | 2 | 2018 | 563 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 213 | 0.050 |
Why?
| | Antigens, CD19 | 1 | 2022 | 91 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2023 | 415 | 0.050 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2021 | 107 | 0.050 |
Why?
| | United Kingdom | 1 | 2021 | 227 | 0.050 |
Why?
| | Busulfan | 1 | 2020 | 14 | 0.050 |
Why?
| | Aminoquinolines | 1 | 2020 | 20 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2021 | 135 | 0.040 |
Why?
| | Carmustine | 1 | 2020 | 47 | 0.040 |
Why?
| | Cytarabine | 1 | 2020 | 51 | 0.040 |
Why?
| | Central Nervous System | 1 | 2021 | 238 | 0.040 |
Why?
| | Acetates | 1 | 2019 | 95 | 0.040 |
Why?
| | Treatment Failure | 1 | 2020 | 332 | 0.040 |
Why?
| | Viral Tropism | 1 | 2018 | 24 | 0.040 |
Why?
| | Guidelines as Topic | 1 | 2020 | 245 | 0.040 |
Why?
| | Ganciclovir | 1 | 2018 | 49 | 0.040 |
Why?
| | Virus Activation | 1 | 2018 | 78 | 0.040 |
Why?
| | Quinazolines | 1 | 2019 | 240 | 0.040 |
Why?
| | Virus Latency | 1 | 2018 | 80 | 0.040 |
Why?
| | Zidovudine | 1 | 2018 | 77 | 0.040 |
Why?
| | Stem Cell Transplantation | 1 | 2019 | 149 | 0.040 |
Why?
| | Standard of Care | 1 | 2016 | 63 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1435 | 0.030 |
Why?
| | Dexamethasone | 1 | 2018 | 317 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 1153 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 275 | 0.030 |
Why?
| | Organ Transplantation | 1 | 2018 | 161 | 0.030 |
Why?
| | Receptors, Interleukin-6 | 1 | 2015 | 34 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2016 | 69 | 0.030 |
Why?
| | Mice | 2 | 2023 | 14927 | 0.030 |
Why?
| | Steroids | 1 | 2015 | 147 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 267 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2019 | 647 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2018 | 1634 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1132 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2018 | 2585 | 0.030 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 534 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1355 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 2894 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 585 | 0.020 |
Why?
| | Animals | 2 | 2023 | 31867 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 3545 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2341 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 2976 | 0.020 |
Why?
|
|
Haverkos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|